Concerns pertaining to data privacy, cybersecurity and the potential for biased responses underscore the imperative to mitigate these issues before…
Sales of hip equipment were $398 million, while knee devices sold $387 million, both beating analysts’ estimates.
The laboratory has been established with the support of Siemens Healthineers Corporate Social Responsibility initiative, which also includes six M.Tech…
Based in Delhi, MediJourney currently has a presence in Bangladesh and Dubai extending its expertise globally.
WHO alerts of a 30-fold surge in Europe’s measles cases, emphasizing urgent vaccination needs.
She is the first from Bangladesh and the second woman Regional Director of WHO South-East Asia Region.
A critical deficiency in mental health professionals plagues India, with merely 0.3 psychiatrists, 0.07 psychologists, and 0.07 social workers available…
With over 50 mutations associated with Gaucher disease, predicting the phenotype or prognosis based on genetic testing proves challenging, leading…
In December 2023, Terumo, a Japanese company, launched Ultimaster Nagomi stent in India, which distinguishes itself by featuring a bioresorbable…
The rise in the use of FXa inhibitors highlights the necessity for a specific reversal agent to mitigate the morbidity…
Rivaroxaban Tablets USP (RLD Xarelto) had estimated annual sales of USD 8,249 million in the U.S. (IQVIA MAT November 2023).
Srinath Venkatesh steps into this pivotal role with a vision to advance Thermo Fisher’s growth and operations in India, while…
Sanofi CEO Paul Hudson has heralded a new era of cutting-edge research and development at the company, emulating rivals like…
Deaths from malaria have been rising in Cameroon since 2017 and almost a third of all hospital consultations are malaria-related,…
The collaboration aligns with the Indian Government’s emphasis on fostering local Research and Development (R&D) and Manufacturing in the MedTech…
With age-standardised incidence and mortality rates of 22 and 12.4 per 100,000 women per year, cervical cancer is the second…
The FDA said in its letters to the companies on Monday that since the approval, it had identified adverse events…
Gilead’s trial included 603 patients with advanced non-small cell lung cancer who didn’t respond to other treatments like chemotherapy or…